342
Participants
Start Date
December 1, 2021
Primary Completion Date
December 31, 2023
Study Completion Date
May 31, 2028
Pembrolizumab
"Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.~Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery."
Paclitaxel
Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
Cisplatin
Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
neoadjuvant chemoradiotherapy
neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week
RECRUITING
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Shanghai Chest Hospital
OTHER
Ruijin Hospital
OTHER
Hebei Medical University Fourth Hospital
OTHER
Harbin Medical University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Shanxi Province Cancer Hospital
OTHER
Jining First People's Hospital
OTHER
Weifang People's Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
Tianjin Medical University Cancer Institute and Hospital
OTHER